The U.S. Food and Drug Administration (FDA) has officially approved Moderna’s mRNA influenza vaccine, a milestone in the company’s efforts to expand its platform beyond COVID-19. The vaccine utilizes the same messenger RNA technology that gained widespread use during the pandemic, which proponents argue allows for faster development and potentially higher efficacy compared to traditional flu shots.

Traditional flu vaccines are typically manufactured using chicken eggs, a process that has remained largely unchanged for decades. The mRNA approach, by contrast, instructs cells to produce a protein that triggers an immune response, theoretically allowing for a more precise match to circulating virus strains. Public health experts have long sought to modernize flu vaccine production to better address the estimated 1 billion infections and 300,000 annual deaths associated with influenza globally.

While the approval is viewed as a technological advancement, the rollout will depend on logistical integration into existing healthcare systems and public uptake. The FDA’s decision follows clinical trial data submitted by Moderna, though the long-term comparative effectiveness against established, non-mRNA vaccines remains a subject of ongoing study. The approval represents a significant expansion of the mRNA platform, which researchers are also investigating for potential use against other respiratory viruses and chronic conditions.